- Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures
- STRIVE data show that 55% of patients on Aimovig 140 mg experienced at least a 50% reduction in the number of monthly migraine days requiring acute medication at week 52
- Data demonstrated sustained efficacy of Aimovig through week 52 in episodic migraine patients who failed prior preventive treatments; reinforcing Novartis’ commitment to reimagine medicine for patients across the spectrum of migraine
- The additional long-term data in a population with prior treatment failures complement Aimovig’s position as the most prescribed anti CGRP, with more than 220,000 patients prescribed worldwide since launch
Basel, July 1, 2019 - Novartis, a global leader in Neuroscience, today announced that new data from the active treatment phase (ATP) of the STRIVE Phase III clinical study will be presented at the European Academy of Neurology (EAN) annual meeting in Oslo, Norway. These additional data demonstrate Aimovig (erenumab) 70 mg and 140 mg significantly reduced monthly migraine days (MMD) and migraine-specific medication days (MSMD) for episodic migraine patients who have previously struggled to find effective and tolerable preventive therapies specifically designed for migraine prevention. These findings add to the breadth of clinical data which show the sustained efficacy of Aimovig across the spectrum of migraine, including in those who have failed prior preventive treatments.